NFA
CDTX

Nationwide Fund Advisors’s Cidara Therapeutics CDTX Stock Holding History

Nationwide Fund Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-410
Closed -$66K – 362
2017
Q3 		$66K Hold
410
– – ﹤0.01% 3008
2017
Q2 		$62K Buy
410
+80
+24% +$11.1K ﹤0.01% 3035
2017
Q1 		$52K Hold
330
– – ﹤0.01% 2976
2016
Q4 		$69K Hold
330
– – ﹤0.01% 2952
2016
Q3 		$76K Sell
330
-700
-68% -$162K ﹤0.01% 2976
2016
Q2 		$212K Buy
1,030
+176
+21% +$42.6K ﹤0.01% 2586
2016
Q1 		$217K Hold
854
– – ﹤0.01% 2500
2015
Q4 		$293K Hold
854
– – ﹤0.01% 2365
2015
Q3 		$217K Buy
854
+350
+69% +$100K ﹤0.01% 2520
2015
Q2 		$141K Buy
+504
New +$155K ﹤0.01% 2894

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nationwide Fund Advisors's CDTX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Cidara Therapeutics (CDTX) in Q4 2017, closing a stake of 410 shares — an estimated $66K sold.

Nationwide Fund Advisors first reported a position in CDTX in Q2 2015 and held it in 10 quarters. The position peaked at $293K in Q4 2015. 48 funds tracked by Wall St. Rank hold CDTX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Cidara Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 410 Cidara Therapeutics shares in Q4 2017, an estimated $66K.
  • Nationwide Fund Advisors first reported a position in Cidara Therapeutics in Q2 2015 and held it in 10 quarters.
  • Nationwide Fund Advisors's Cidara Therapeutics position peaked at $293K in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.